{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Morgantown",
      "state": "WV",
      "country": "United States",
      "classification": "Class III",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "80261",
      "recalling_firm": "Mylan Pharmaceuticals Inc.",
      "address_1": "781 Chestnut Ridge Rd",
      "address_2": "N/A",
      "postal_code": "26505-2730",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Product was distributed throughout the United States",
      "recall_number": "D-0877-2018",
      "product_description": "Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/  25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01",
      "product_quantity": "1,620 bottles",
      "reason_for_recall": "Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.",
      "recall_initiation_date": "20180607",
      "center_classification_date": "20180615",
      "termination_date": "20190620",
      "report_date": "20180620",
      "code_info": "Lot #: 3087136, Exp 5/20"
    }
  ]
}